Menu Search
Equities

Surgery Partners Inc

1SP:DUS

Surgery Partners Inc

Actions
  • Price (EUR)26.00
  • Today's Change-1.80 / -6.47%
  • Shares traded0.00
  • 1 Year change+4.00%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 15:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Surgery Partners Inc grew revenues 8.03% from 2.54bn to 2.74bn while net income improved from a loss of 54.60m to a smaller loss of 11.90m.
Gross margin26.59%
Net profit margin3.54%
Operating margin10.82%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, cash reserves at Surgery Partners Inc fell by 87.00m. However, the company earned 293.80m from its operations for a Cash Flow Margin of 10.71%. In addition the company used 225.60m on investing activities and also paid 155.20m in financing cash flows.
Cash flow per share2.03
Price/Cash flow per share14.71
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in USDView more

Surgery Partners Inc uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.